Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Janssen Pharmaceutica NV - Guiding clinical decision-making in advanced EGFR-mutant NSCLC

Navigating the current treatment landscape for common EGFR-mutant NSCLC

Date

21 Mar 2024

Session

Janssen Pharmaceutica NV - Guiding clinical decision-making in advanced EGFR-mutant NSCLC

Presenters

Raffaele Califano, Jordi Remon Masip

Authors

R. Califano1, J. Remon Masip2

Author affiliations

  • 1 The Christie NHS Foundation Trust, Manchester/GB
  • 2 Institut Gustave Roussy, Villejuif, Cedex/FR

Resources

This content is available to ESMO members and event participants.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.